Lamisil side effects by duration, gender and age - a phase IV clinical study of FDA data
Side effects are reported by people who take Lamisil. Common side effects include ageusia among females and drug effect decreased among males.
The phase IV clinical study is created by eHealthMe based on 13,049 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
13,049 people who take Lamisil and have side effects are studied.
What is Lamisil?
Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 13,652 Lamisil users for its effectiveness, alternative drugs and more.
Number of Lamisil reports submitted per year:
Lamisil side effects by time on the drug *:
Lamisil side effects by gender *:
Lamisil side effects by age *:
* Approximation only. Some reports may have incomplete information.
Do you take Lamisil?Personalize this study to your gender and age
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How the study uses the data?
The study is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.
Alternative drugs to, pros and cons of Lamisil:
- Lamisil (13,652 reports)
Common Lamisil side effects:
- Rashes (redness): 916 reports
- Itching: 743 reports
- Fever: 646 reports
- Fatigue (feeling of tiredness): 599 reports
- Weight decreased: 568 reports
All Lamisil side effects from A to Z:a b c d e f g h i j k l m n o p q r s t u v w x y z
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Imdur vs. Fludrocortisone Acetate - 5 seconds ago
- Clobazam and Upper Respiratory Tract Infection - 11 seconds ago
- Rituxan and Csf Collection - 13 seconds ago
- Duopa and Hypokalemia - 13 seconds ago
- Drug Abuse And Dependence and drugs of ingredients of ashwagandha - 20 seconds ago
- Kadian and Nucynta Er drug interaction - 23 seconds ago
- Rituxan and Vertebral Column Mass - 23 seconds ago
- Colace and Fenofibrate drug interaction - 23 seconds ago
- Alecensa and Chantix drug interaction - 24 seconds ago
- Social Phobia and drugs of ingredients of peginterferon alfa 2a - 25 seconds ago